Evidence map›Paper›PMID 32297992›Full record

Trial reportJournal of clinical pharmacology2020

Severity of Topiramate-Related Working Memory Impairment Is Modulated by Plasma Concentration and Working Memory Capacity.

Samuel P Callisto, Sílvia M Illamola, Angela K Birnbaum, Christopher M Barkley, Sai Praneeth R Bathena, Ilo E Leppik, Susan E Marino

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The Effect of Zonisamide and Ethanol on Various Types of Memory in Rats.International journal of environmental research and public health · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Samuel P CallistoExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0003-3148-2498
Sílvia M IllamolaExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
Angela K BirnbaumExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
Christopher M BarkleyExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
Sai Praneeth R BathenaExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
Ilo E LeppikExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
Susan E MarinoExperimental and Clinical Pharmacology Department, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · US

Funding

TREATMENT OF PATIENTS WITH PSEUDO-SEIZURESP50NS016308 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LEPPIK, ILO E · 1985 to 2006
$8.5M
Characterizing and Predicting Drug Effects on CognitionR01NS076665 · NINDS · UNIVERSITY OF MINNESOTA · PI MARINO, SUSAN E · 2012 to 2016
$2.7M
NINDS NIH HHS P50 NS016308NINDS NIH HHS R01 NS076665
6 · The paper itself

Abstract

Drug side effects that impair cognition can lead to diminished quality of life and discontinuation of therapy. Topiramate is an antiepileptic drug that elicits cognitive deficits more frequently than other antiepileptic drugs, impairing multiple cognitive domains including language, attention, and memory. Although up to 40% of individuals taking topiramate may experience cognitive deficits, we are currently unable to predict which individuals will be most severely affected before administration. The objective of this study was to show the contributions of plasma concentration and working memory capacity in determining the severity of an individual's topiramate-related cognitive impairment. Subjects were enrolled in a double-blind, placebo-controlled crossover study during which they received a single dose of either 100, 150, or 200 mg topiramate. Working memory function was assessed using a modified Sternberg working memory task with 3 memory loads administered 4 hours after dosing. After adjustment for differences in working memory capacity, each 1 μg/mL of topiramate plasma concentration was associated with a 3.6% decrease in accuracy for all memory loads. Placebo effects occurred as a function of working memory capacity, with individuals with high working memory capacity experiencing less severe placebo-related impairment compared with those with low working memory capacity. Our results demonstrate that severity of topiramate-related cognitive deficits occurs as a function of both drug exposure and baseline cognitive function. By identifying patient- and exposure-related characteristics that modulate the severity of cognitive side effects, topiramate dosing strategies may be individually tailored in the future to prevent unwanted cognitive impairment.

Indexed as

AdolescentAdultAnticonvulsantsCognitionCognitive DysfunctionCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMemory, Short-TermModels, BiologicalNeuropsychological TestsTopiramateAnticonvulsantsTopiramatecognitive impairmentmodelingpharmacokinetic/pharmacodynamictopiramateworking memory

Identifiers

PMID32297992
PMCPMC7572737
OpenAlexW3016772319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.